ClinicalTrials.gg
RecruitingNCT07040930Updated Aug 6, 2025

Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China.

A Phase 1 interventional study of GenSci120 and Placebo in Rheumatoid Arthritis, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-06.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 249 studies in Arthritis, Rheumatoid with a site in China — 63 open to participants now, 72 under way, 3 of them phase 3. Arthritis, Rheumatoid · China.

Planned enrollment
173rd of 217
30 · median 134
Started
2025
with 34 others
Phase 1
54 of 249
20 open now
Primary completion
2026-07
later than 28 of 71 live
Registered
210th of 249
by date

Among the 249 studies in Arthritis, Rheumatoid with a site in China, this one is the 173rd largest by planned enrollment of the 217 interventional ones that give a count, is one of 35 that started in 2025, is one of 54 in phase 1, reaches primary completion later than 28 of the 71 other live ones, and was the 210th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

63 of the 249 studies in Arthritis, Rheumatoid with a site in China are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies in Arthritis, Rheumatoid with a site in China, or all of them as a file.
02

Study summary

This study is designed to evaluate the safety, tolerability, PK and PD of multiple subcutaneous injections of GenSci120 in a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase Ib trial involving healthy adult participants.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • phase Ib
  • healthy adult
  • multiple subcutaneous injections
  • GenSci120
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ages 18-55; ≥3 per gender for each cohort.
  2. : 18-30; Weight: ≥50 kg (male), ≥45 kg (female).
  3. No abnormalities in medical history, physical exam, vital signs, or lab//pulmonary imaging.
  4. Men/ must use effective throughout study; no plans to conceive; WOCBP must have negative pregnancy test and not breastfeeding. Women of non-childbearing potential: post-hysterectomy/salpingectomy or (FSH >40 IU/L).
  5. Able to provide ; willing to comply with all study requirements

Exclusion criteria

Exclusion Criteria:

  1. Allergy to GenSci120 or severe allergies.
  2. Injection site issues affecting evaluation.
  3. Significant medical conditions impacting study outcome.
  4. History of malignant tumors, including listed cancers.
  5. Seizure history, head injury causing unconsciousness.
  6. Psychiatric disorders impairing daily activities or cognitive issues.
  7. Severe immunodeficiency (e.g., ).
  8. Recent trauma, surgery, or GI issues affecting absorption.
  9. Recent severe infections or antimicrobial treatments.
  10. within a month prior to screening.
  11. Abnormal vital signs/: BP extremes, >450ms.
  12. Positive for /C, HIV, syphilis during screening.
  13. Positive TB test via IGRA.
  14. Recent use of or targeted therapies.
  15. Medication use within 14 days prior to randomization.
  16. Participation in other clinical trials recently/currently.
  17. Excessive alcohol consumption (over six months).
  18. Heavy smoking, unwillingness to quit, positive nicotine tests.
  19. Positive drug screen for specific substances.
  20. Recent soft/hard drug use within specified periods.
  21. Blood donation/product receipt recently or poor venous access.
  22. Study staff involved in the trial.
  23. Other conditions deemed unsuitable by investigators.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    GenSci120

    Multiple ascending doses of GenSci120 administered subcutaneously (SC).

    Drug: GenSci120

  • Experimental
    Placebo

    Multiple ascending doses of placebo administered subcutaneously (SC).

    Drug: Placebo

Interventions

  • a total of 3 doses of the investigational medicinal product (IMP) SC every four weeks (Q4W) at the planned dose level

  • DrugPlacebo

    a total of 3 doses of the investigational medicinal product (IMP) SC every four weeks (Q4W) at the planned dose level

06

What researchers measure

Primary outcomes

  1. TEAEs

    Incidence and severity of treatment-emergent adverse events

    Time frame: 169 days

  2. SAEs

    Incidence and severity of serious adverse events

    Time frame: 169 days

  3. CSfadf

    Clinically significant changes from baseline

    Time frame: 169 days

Secondary outcomes

  1. plasma

    Concentration of GenSci120 in plasma samples.

    Time frame: 169 days

  2. AUC0-t, AUC0-∞

    Area under drug concentration-time curve

    Time frame: 169 days

  3. Tmax

    time to maximum concentration

    Time frame: 169 days

  4. Cmax

    maximum concentration

    Time frame: 169 days

  5. t1/2

    169 days

    Time frame: half-life

  6. CL/F

    169 days

    Time frame: apparent clearance

  7. V/F

    apparent volume of distribution

    Time frame: 169 days

  8. RO of T cell subset

    Receptor occupancy (RO) of T cell subset detected by flow cytometry

    Time frame: 169 days

  9. cell counts of T cell subset

    cell counts of T cell subset detected by flow cytometry

    Time frame: 169 days

  10. Incidence of ADA

    Incidence of anti-drug antibody (ADA) positive positive (if applicable) after GenSci120 administration

    Time frame: 169 days

  11. Time of ADA

    Time of anti-drug antibody (ADA) positive positive (if applicable) after GenSci120 administration

    Time frame: 169 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jul 2026, 11 months after the start.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 11 months is below that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2025
First posted
Jun 27, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Jul 5, 2026
CompletionEst.
Sep 20, 2026
Last update
Aug 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07040930
Responsible party
Sponsor
First posted
Jun 27, 2025
Start date
Aug 1, 2025
Primary completion
Jul 5, 2026 (estimated)
Completion
Sep 20, 2026 (estimated)
Last update
Aug 6, 2025

Study contacts

Yiting Chi, Master
Contact
chiyiting@genscigroup.com
+86 13482779422
Jing Zhang, M.D.
principal investigator · Huashan Hospital
Xiaojie Wu, M.D.
principal investigator · Huashan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GENSCI120

Start the discussion